Concepedia

Ann Mohrbacher

AM

19

Publications

1.7K

Citations

15

H-Index

1992

Active since

Affiliations

University of Southern California(Current)

Dana-Farber Cancer Institute

Northwestern University

The Barbara Ann Karmanos Cancer Institute

Azienda Ospedaliero-Universitaria di Modena

Ann Mohrbacher is an author at University of Southern California specializing in hematology, medicine, and oncology.

ORCID

Top concepts

Publications per year

1992–2023

19

Publications

19

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal et al. · Blood · 2011 · 339 citations · Full text

Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab

Thomas A. Davis, Christine A. White, A.J. Grillo-López et al. · Journal of Clinical Oncology · 1999 · 289 citations

, , +16

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Andrzej Jakubowiak, Massimo Offidani, Brigitte Pegourié et al. · Blood · 2016 · 231 citations · Full text

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

Andrzej Jakubowiak, Don M. Benson, William Bensinger et al. · Journal of Clinical Oncology · 2012 · 202 citations · Full text

TRALI due to granulocyte‐agglutinating human neutrophil antigen‐3a (5b) alloantibodies in donor plasma: a report of 2 fatalities

Anne Davoren, Brian R. Curtis, Ira A. Shulman et al. · Transfusion · 2003 · 161 citations

Rows per page

1–5 of 19